| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.18 | 0.03 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.064 | 0.03 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.069 | 0.04 |
| mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.22 | 0.04 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.078 | 0.04 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.073 | 0.04 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.04 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | -0.061 | 0.05 |
| mRNA | neopeltolide | CTRPv2 | pan-cancer | AAC | -0.15 | 0.05 |